Skip to main content
. 2021 Aug 15;18(3):841–848. doi: 10.20892/j.issn.2095-3941.2020.0413

Table 2.

DLTs in the phase 1b study

Chidamide dose Patients treated (n) DLT (n) Toxicity Best response
15 mg biw 6 1 Grade 3 pulmonary infection 2CR, 1PR
20 mg biw1 6 1 Grade 4 neutropenia with G-CSF support 2CR
25 mg biw 3 2 Grade 4 neutropenia with G-CSF support 2PR

DLT, dose limited toxicity; CR, complete response; PR, partial response; G-CSF, granulocyte colony-stimulating factor.

1Maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D).